The 13 genes, eight of which are involved in the processing of fat in the body, could also be targeted by drugs leading to new treatments for non oestrogen-sensitive breast cancer, they reported in the Cancer Prevention Research journal.

Prof Seema Khan of Northwestern University in Chicago, who led the study, explained: "We now have the possibility of predicting if a preventive drug will work for a woman at high risk of breast cancer, so that we don't expose women to the risks and side effects of this drug if it won't help them.

"Identifying these genes also gives us a target for new therapies. Once we understand what regulates these genes, we can try to develop a therapy to switch them off."

About seven in ten breast cancers are "hormone receptor positive", meaning they are sensitive to oestrogen, but a significant proportion, particularly in younger women and women of African origin, are "HR negative".

Researchers studied a group of women who had developed cancer in one breast, meaning any tumour to grow in their other breast in future would likely be of the same type.

In samples of tissue from the healthy breast, the team identified 13 genes which were more or less active depending on whether the women's tumours were HR positive or negative.

Eight of the genes were involved in the metabolism of fat and several had previously been identified at high levels in breast tumour cells, backing up the findings.

Dr Emma Smith of Cancer Research UK said further study was needed but the results could lead to doctors "lowering the threshold" for deciding which patients are given tamoxifen, because they will be more sure who will benefit from it.

"If you stop breast cancer developing, you reduce the number of women who will need chemotherapy, surgery, mastectomies, and so on," she said.

See original here:
Breast cancer gene test could allow preventive treatment

Recommendation and review posted by Bethany Smith

The market for bioinformatics services and software may soon surpass that for sequencing technologies, such as the one depicted here, in which laser light is used to help sequence DNA in glass slides.

David Paul Morris/Bloomberg via Getty Images

For Chaim Jalas at the Center for Rare Jewish Genetic Disorders in New York, DNA sequencing is the easy part. It costs less than US$1,500 per person to have the important parts of his clients genomes sequenced. But it would be dauntingly expensive to maintain servers and staff to analyse the data and identify mutations that might be causing the undiagnosed diseases that afflict his clients families.

So Jalas, the centres director of genetics resources and services, has outsourced parts of the analysis. He uploads his clients sequencing data to cloud-computing software platforms, where he can run analyses without having to set up the infrastructure in-house. The cost is about $100 per person. And the cloud-based interfaces let him collaborate with doctors in Israel without worrying about repeatedly transferring data on slow Internet connections. For me, it is convenient and cost-efficient, he says.

Jalas and the way he works represent a new and mostly untapped market for a new crop of genetics interpretation and analysis firms, which will be touting for customers at a meeting of the American College of Medical Genetics and Genomics in Phoenix, Arizona, on 1923March. Dozens of these firms have emerged, some in the past year, as ever more affordable sequencing moves from academia into the clinic (see Nature 494, 290291; 2013). Doctors will increasingly want to use sequencing data to guide decisions about patient care, but might not necessarily want to invest in staff and software to make sense of those data.

Its a huge unmet need, says David Ferreiro, a biotechnology analyst with investment bank Oppenheimer & Company in New York, which invests in many sequencing-technology and -analysis companies.

Where there is a need, there is also money to be made. The companies, many of them based in Californias Silicon Valley, have been tempted by a market in outsourced sequencing and analysis software that by 2016 could top $4billion per year, according to BCC Research, a market-research company in Wellesley, Massachusetts (see Genes in the marketplace). The skys the limit, says Andreas Sundquist, chief executive of DNAnexus in Mountain View, California, which provides genetic-analysis software on its cloud-based platform and allows users to upload and run their own algorithms.

Source: BCC Research

Other firms offer a range of approaches. Seven Bridges Genomics, based in Cambridge, Massachusetts, aims to be accessible to people with no expertise in bioinformatics, and provides access to free tools for designing custom-made analysis pipelines. Ingenuity Systems in Redwood City, California, allows users to upload a list of mutations in a persons genome, and finds those most likely to cause disease. Personalis, down the road in Menlo Park, offers sequencing services and interpretation for clinicians and pharmaceutical and biotechnology companies. Last week, the company won a $1.53-million contract with the US Department of Veterans Affairs to look for genetic variants in samples from as many as onemillion military veterans, to explore the variants roles in disease. (The company will outsource the sequencing to Illumina, a market leader in sequencing technology based in San Diego, California.)

The activity is reminiscent of that a decade ago, when bioinformaticians started up a flurry of companies, most of which were unsuccessful because the path from a genetic-disease marker to a profitable drug has not been straightforward. Todays companies have moved on to other challenges, says Steven Brenner, a computational genomicist at the University of California, Berkeley. He says that they will have to prove that their products are better than freely available software and do so without disclosing their intellectual property. These companies have a tricky situation, he says.

Excerpt from:
Gene -analysis firms reach for the cloud

Recommendation and review posted by Bethany Smith

Public release date: 19-Mar-2013 [ | E-mail | Share ]

Contact: Jeremy Moore jeremy.moore@aacr.org 215-446-7109 American Association for Cancer Research

PHILADELPHIA The overexpression or underexpression of a newly identified set of genes related to lipid metabolism may help physicians identify whether or not a woman is at risk for hormone receptor-positive or hormone receptor-negative breast cancer and to subsequently tailor prevention strategies appropriately, according to data published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

"Currently, three drugs can be used to prevent breast cancer in women who are at extremely high risk for the disease," said Seema A. Khan, M.D., co-leader of the Breast Cancer Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago. "However, these drugs prevent only breast cancers that are sensitive to hormones, commonly referred to as estrogen receptor-positive breast cancers; they do not prevent breast cancers that are insensitive to hormones, or estrogen receptor-negative breast cancers.

"We should not expose women at risk for hormone-insensitive breast cancer to the side effects of preventive medications that we know will not work for them," Khan said. "Moreover, if we knew who these women were, we could focus on them in terms of designing new studies to find a solution for preventing hormone-insensitive cancer."

Khan and colleagues sought to find a way to identify women at risk for estrogen receptor-negative breast cancer by examining gene expression in the unaffected breasts of women who had a primary breast cancer of known estrogen-receptor status.

They used this approach because prior research has indicated that if women who have had cancer in one breast subsequently develop a cancer in their second breast, the second cancer is likely to have hormone-receptor status that resembles the first cancer.

Using this logic, Khan and colleagues performed fine-needle aspiration on the unaffected breasts of 15 women with estrogen receptor-positive breast cancer and 15 women with estrogen receptor-negative breast cancer. They validated their results in a second group of women: 12 with estrogen receptor-positive disease, 12 with estrogen receptor-negative disease and 12 healthy controls. The cases in each set were matched by age, race and menopausal status.

The researchers identified 13 genes with significantly higher expression levels in samples from estrogen receptor-negative women. Eight of these genes were associated with lipid metabolism.

"This was interesting because obesity is a breast cancer risk factor for postmenopausal women, but obese women are generally thought to be at increased risk for hormone-sensitive cancer," Khan said. "We were surprised to see that some of these genes that are associated with lipid metabolism, or the metabolism of fats, are actually more highly expressed in the unaffected breasts of women with estrogen receptor-negative breast cancer."

See the original post:
Gene profile may help identify risk for hormone-sensitive, hormone-insensitive breast cancer

Recommendation and review posted by Bethany Smith

WATERTOWN, Mass.--(BUSINESS WIRE)--

Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced that the United States Patent and Trademark Office (USPTO) has issued patent claims specific to double-stranded RNAs directed against the important oncology gene target KRAS. U.S. patent 8,372,816, titled Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA was recently issued to Dicerna. This issuance continues the expansion of Dicernas patent portfolio around RNAi-related technology, including the DsiRNA class defining claims of U.S. patent 8,084,599, titled Methods and compositions for the specific inhibition of gene expression by double-stranded RNA.

We are extremely pleased the USPTO has granted these most recent patent claims specific to the KRAS gene, further adding to our strong patent estate and allowing for broad therapeutic use claims in the RNAi field, said Douglas Fambrough, chief executive officer of Dicerna. The KRAS gene has been recognized as a target of great therapeutic potential for decades, and yet has remained undruggable. The successful application of Dicer Substrate Technology against KRAS is a key advancement that could lead to important new therapeutics for cancer treatment.

On February 26, 2013, scientists from Kyowa Hakko Kirin Co., Ltd. (KHK) presented a talk entitled Development of Lipid Nanoparticle (LNP) Based Delivery System of siRNA Targeting Extrahepatic Tumor, at Asia TIDES: Oligonucleotide and Peptide Research, Technology and Product Development. The presentation highlighted in vivo tumor efficacy data obtained with DsiRNA targeting the KRAS gene, one of the programs from the research and development collaboration between Dicerna and KHK. The partners had previously announced in December 2011 that KHK had elected to advance this first collaborative therapeutic oncology candidate from the research stage into formal development studies, triggering a $5 million milestone payment for Dicerna.

About Dicer Substrate RNAi

Dicer is a critical enzyme involved in the RNAi gene silencing cascade and acts as the natural initiation point for this pathway by processing double-stranded RNA so that it can be used for gene silencing. Dicer then delivers these modified small RNA molecules to the mature gene silencing complex. Dicernas synthetic Dicer Substrate siRNA (DsiRNA) molecules are 25 or more base pairs in length and are processed by Dicer. By utilizing this distinct early entry point into the pathway, DsiRNA molecules have greater potency and longer duration of action than other RNAi approaches. In addition, DsiRNA molecules have enhanced delivery potential because their structure creates a natural conjugation point for cellular targeting agents.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a private, venture-backed RNAi-focused biopharmaceutical company developing novel therapeutic agents and related drug delivery systems in oncology and other disease areas based on its proprietary Dicer Substrate Technology platform and Dicer Substrate siRNA (DsiRNA) molecules. Dicer Substrate Technology is a second generation RNAi approach that results in greater potency, longer duration of action and enhanced delivery potential, differentiating it from other RNAi approaches. Dicerna has a major alliance with Kyowa Hakko Kirin for DsiRNA pharmaceuticals and drug delivery systems focused in oncology, immunology and inflammation. The company also has a partnership with Ipsen to research and develop novel DsiRNA therapeutics with targeted delivery in oncology and endocrinology. Dicerna is based in Watertown, Massachusetts. For more information, please visit http://www.dicerna.com.

About Kyowa Hakko Kirin

Kyowa Hakko Kirin is a leading biopharmaceutical company in Japan focusing on its core business area of oncology, nephrology and immunology/allergy. Kyowa Hakko Kirin leverages antibody-related leading-edge technologies to discover and develop innovative new drugs aiming to become a global specialty pharmaceutical company which contributes to the health and well-being of people around the world. For more information, visit http://www.kyowa-kirin.com.

The rest is here:
Dicerna Announces Patent Issuance for DsiRNAs Directed at the KRAS Gene , a Key Cancer Regulator

Recommendation and review posted by Bethany Smith

Newswise DURHAM, NC Newly identified mutations in a gene that makes cells immortal appear to play a pivotal role in three of the most common types of brain tumors, as well as cancers of the liver, tongue and urinary tract, according to research led by Duke Cancer Institute.

The finding, published Monday, March 18, 2013, in the journal Proceedings of the National Academy of Sciences, provides a long-sought answer to how some malignant cells are able to proliferate, while normal cells peter out and die.

This key to immortality involves telomeres, the end tabs that protect chromosomes from sticking together or fraying. As normal cells divide, the telomeres gradually grow shorter until they become so short the cell stops dividing and it expires. An enzyme called telomerase serves as a sort of growth factor, temporarily maintaining the length of the telomeres and enabling the cell to continue proliferating.

Scientists have recently learned that mutations of the so-called TERT promoter gene, which controls the instructions for making the telomerase enzyme, is involved in some cancer tumors. It appears that a mutation of the TERT promoter gene essentially creates a constant growth spurt so that the telomeres never shorten, and the cells can divide forever. Earlier this year, the process was described as a leading contributor to melanomas and a small number of other tumors.

The current research expands those findings by analyzing more than 1,200 tumors across 60 different types of cancer. Led by Hai Yan, M.D., PhD, a professor of pathology and investigator with Dukes Preston Robert Tisch Brain Tumor Center, the research team includes collaborators at Johns Hopkins and multiple other institutions.

The researchers found almost no TERT promoter mutations in many major cancer types, including breast and prostate malignancies, suggesting that some yet-unknown factor is causing the telomeres to elongate and promote cell immortality in those diseases.

But the Duke-led research team also identified nine tumor types highly associated with TERT promoter mutations. These cancers generally share a common feature: they arise in tissues with relatively low rates of cell renewal, suggesting they require the mutation to trigger the abnormal telomerase production.

These cancer types include melanomas, liposarcomas, hepatocellular carcinomas, transitional cell carcinomas of the urinary tract, squamous cell carcinomas of the tongue, medulloblastomas, and subtypes of gliomas, including 83 percent of primary glioblastomas, the most common brain tumor in adults with a median survival of only 15 months.

The results in brain tumors were quite striking, said Patrick J. Killela, co-lead author of the study and a Duke graduate student. For primary glioblastoma, this is the most frequent genetic mutation yet identified in this tumor.

Four years ago, Yans laboratory at Duke identified critical gene mutations associated with glioblastoma. But those mutations in the IDH1 and IDH2 genes -- were found only in rare glioblastomas that arose from other, lower-grade tumors known as astrocytomas and oligodendrogliomas. The main cancer-causing mutation for the other primary glioblastomas remained elusive.

More here:
Immortality Gene Mutation Identifies Brain Tumors and Other Cancers

Recommendation and review posted by Bethany Smith

March 19, 2013

April Flowers for redOrbit.com Your Universe Online

Certain diseases are caused by single gene mutations, and with current techniques for identifying the disease-causing gene producing hundreds of potential gene candidates, it is difficult for scientists to pinpoint the single causative gene. New research led by Rockefeller University scientists has led to the creation of a map of gene shortcuts to simplify the hunt for disease-causing genes.

Yuval Itan, a postdoctoral fellow in the St. Giles Laboratory of Human Genetics of Infectious Diseases, spearheaded the investigation that has led to the creation of what he calls the human gene connectome. The connectome is the full set of distances, routes (the genes on the way), and degrees of separation between any two human genes. Itan, a computational biologist, says the program he designed to generate the connectome uses the same principles GPS navigation uses to plan a trip between two locations.

The research team reported their findings in the online early edition of Proceedings of the National Academy of Sciences (PNAS).

High throughput genome sequencing technologies generate a plethora of data, which can take months to search through, says Itan. We believe the human gene connectome will provide a shortcut in the search for disease-causing mutations in monogenic diseases.

The team designed applications for use of the human gene connectome, beginning with a gene called TLR3, which is important for resistance to herpes simplex encephalitis a life threatening infection from the herpes virus that can cause significant brain damage in genetically susceptible children. Previous research from the St. Giles laboratory, led by Jean-Laurent Casanova, revealed children with HSE have mutations in TLR3 or in genes that are closely functionally related to TLR3. To follow the GPS metaphor, these genes are biologically a short distance from TLR3, leading scientists to believe novel herpes simplex encephalitis-causing genes are also expected to have a short biological distance from TLR3.

The team included researchers from the Necker Hospital for Sick Children, the Pasteur Institute in Paris, and Ben-Gurion University in Israel. They tested the capability of the human gene connectome to predict a disease-causing gene by sequencing exomes, (which are all DNA of the genome that is coding for proteins), of two patients recently shown to carry mutations of a separate gene, TBK1.

Each patients exome contained hundreds of genes with potentially morbid mutations, says Itan. The challenge was to detect the single disease-causing gene.

The researchers sorted the genes by their predicted biological proximity to TLR3, finding TBK1 at the top of the list in both patients. They successfully predicted two other genes, EFGR and SRC, as part of the TLR3 pathway before they were experimentally validated, using the TLR3 connectome. They applied other gene connectomes the set of all human genes sorted by their distance to a particular gene to detect Ehlers-Danlos syndrome and sensorineural hearing loss disease causing genes.

Continued here:
Shortcut Map Could Simplify The Hunt For Disease-Causing Genes

Recommendation and review posted by Bethany Smith

Body Of Osama Bin Laden Found! SATIRE
Yes it is true! This is huge! This is SATIRE or a JOKE for people that don #39;t know what satire is.

By: TheAlexJonesChannel

Visit link:
Body Of Osama Bin Laden Found! SATIRE - Video

Recommendation and review posted by Bethany Smith

Public release date: 18-Mar-2013 [ | E-mail | Share ]

Contact: Bill Schappert bschappert@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, March 18, 2013The more than 100 million Americans living with chronic pain and daily suffering often have limited outlets to talk about their conditions with others who can understand and offer comfort. Online chatrooms may provide a beneficial forum where chronic pain sufferers can openly and safely communicate, as discussed in an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free online on the Cyberpsychology, Behavior, and Social Networking website.

In "Cyberhugs: Creating a Voice for Chronic Pain Sufferers through Technology," author Karin Becker, University North Dakota, Grand Forks, describes the social stigma, gender politics, and professional repercussions that often discourage people affected by chronic pain from talking about it. Her study of the role that online chatrooms dedicated to individuals with chronic pain can have in establishing a sense of community revealed two key themes: the importance of validation and encouragement.

"Online chatrooms may provide another outlet for support for chronic pain sufferers and may work towards removing barriers this population often experiences," says Brenda K. Wiederhold, PhD, MBA, BCIA, Editor-in-Chief of Cyberpsychology, Behavior, and Social Networking, from the Interactive Media Institute, San Diego, CA.

###

About the Journal

Cyberpsychology, Behavior, and Social Networking is a peer-reviewed journal published monthly online with Open Access options and in print that explores the psychological and social issues surrounding the Internet and interactive technologies, plus cybertherapy and rehabilitation. Complete tables of content and a sample issue may be viewed on the Cyberpsychology, Behavior, and Social Networking website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Games for Health Journal, Telemedicine and e-Health, and Journal of Child and Adolescent Psychopharmacology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

More here:
Can online chat rooms and 'cyberhugs' help chronic pain sufferers cope?

Recommendation and review posted by Bethany Smith

Public release date: 19-Mar-2013 [ | E-mail | Share ]

Contact: Vicki Cohn vcohn@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, Mar 19, 2013Chronic fatigue, a persistent lack of energy that does not improve with rest, is at least three times more prevalent among adult survivors of acute lymphoblastic leukemia and lymphoma experienced during childhood or adolescence than in the general adult population, according to an article in Journal of Adolescent and Young Adult Oncology (JAYAO), (http://www.liebertpub.com/JAYAO) a multidisciplinary peer-reviewed publication from Mary Ann Liebert, Inc., publishers. (http://www.liebertpub.com) JAYAO is the Official Journal of the Society for Adolescent and Young Adult Oncology (http://www.sayao.org). The article is available online on the JAYAO (http://www.liebertpub.com/JAYAO) website.

Chronic fatigue can negatively affect a person's health-related quality of life and ability to work and carry out normal daily functions. Authors Hanne Hamre, MD and colleagues Oslo University Hospital and University of Oslo Norway used a questionnaire, clinical examination, and blood samples to compare adult survivors of childhood leukemia and lymphoma to a control group from the general population. The prevalence of chronic fatigue was 27% among the cancer survivors compared to 8% among controls.

In the article "High Prevalence of Chronic Fatigue in Adult Long-Term Survivors of Acute Lymphoblastic Leukemia and Lymphoma during Childhood and Adolescence," (http://online.liebertpub.com/doi/full/10.1089/jayao.2012.0015) the authors describe factors predictive of chronic fatigue among the adult cancer survivors and present blood analysis findings suggestive of a persistent low-grade inflammatory response that may contribute to the chronic fatigue.

"Chronic fatigue in cancer survivors is often an under-appreciated complication of treatment," says Editor-in-Chief Leonard S. Sender, MD, of the University of California, Irvine and CHOC Children's Hospital. "There is a general belief that after successful treatment a survivor should be able to bounce back without lasting effects. Hamre and colleagues demonstrate that fatigue is a larger problem than generally appreciated. Their findings put a spotlight on this key aspect of cancer survivorship and serve to encourage the medical community to communicate with cancer survivor patients about possible chronic fatigue."

###

About the Journal

Journal of Adolescent and Young Adult Oncology (JAYAO) (http://www.liebertpub.com/JAYAO) is a quarterly peer-reviewed journal, published online with Open Access options (http://www.liebertpub.com/openaccess/jayao) and in print, dedicated to the promotion of interdisciplinary research, education, communication, and collaboration between health professionals in AYA oncology. JAYAO provides a forum for AYA cancer research and practice advances for all professional participants and researchers in care for AYA-aged cancer patients and survivors. Our multidisciplinary editorial board and readership includes but is not limited to: pediatric, medical, and surgical oncologists of all types and specialties; oncology nurses and advanced practice staff; psychosocial and supportive care providers including psychiatrists, psychologists, and social workers; translational cancer researchers; and academic- and community-based pediatric and adult cancer institutions. Complete tables of content and a sample issue (http://online.liebertpub.com/toc/jayao/1/1) are available on the Journal of Adolescent and Young Adult Oncology (JAYAO) (http://www.liebertpub.com/JAYAO) website.

About the Society

Read more from the original source:
Are survivors of childhood leukemia and lymphoma at greater risk of chronic fatigue as adults?

Recommendation and review posted by Bethany Smith

Advances in genetic engineering have some biologists convinced theyll re-create extinct species.

Home to roost: The last living passenger pigeon, Martha, can be found, stuffed, in the National Museum of Natural History in Washington, D.C.

Passenger pigeons once darkened the skies over the eastern United States. Huge flocks would roost on chestnut trees, their weight snapping off branches. By 1914, though, humans had hunted the bird to extinction.

Now, a project to reanimate the pigeon using genetic engineering is drawing new attention to the question of de-extinction, or whether biotechnology can help conserve rare animals and even restore others that dissapeared eons ago.

The passenger pigeon effort, known as Revive and Restore, is being paid for by the Long Now Foundation, a nonprofit led by entrepreneur and author Stewart Brand (see Environmental Heresies), who has been stirring interest in the idea of de-extinction by organizing meeting of key researchers, including one last week at the National Geographic Society in Washington, D.C.

Some scientists are convinced the technology is feasible. Not only is sequencing of extinct genomes a reality, but revival of extinct species is within reach, said Hendrik Poinar, a researcher at McMaster University in Ontario, Canada.

The idea of reviving extinct species first gained attention a decade ago, after Dolly the sheep was born via cloning. Since then, advances in DNA sequencing have made it theoretically possible to bring back even ancient species, like the woolly mammoth. Already, researchers have re-created some micorganisms, like the 1918 flu virus, from genetic material found in corpses from the period. Some leading scientists are also creating astartup company that intends to help implement de-extinction (see A Stealthy De-Extinction Startup.)

Its going to be iterative and a convergence of technologies, said Ryan Phelan, a biotech entrepreneur who is married to Brand. I think de-extinction is an empowering face for applying genomics in new domains.

Globally, there appear to be about half a dozen projects aimed at re-creating extinct animals. Those most likely to succeed in the near term involve cases where researchers have access to cells preserved in liquid nitrogen.

In Australia, for instance, researcher Mike Archer of the University of New South Wales says he is now trying to clone the gastric breeding frog, an species known for gestating its young in its stomach and giving birth through its mouth. Archer says hes using cells frozen by a colleague in the 1970s, shortly before the last of the animals disappeared.

Read the rest here:
An Unlikely Plan to Revive the Passenger Pigeon

Recommendation and review posted by Bethany Smith

Re "Genetic crops, world food supply on UCD agenda" (Our Region, March 17): Edward Ortiz raises important questions regarding the relevance of genetically engineered crops to efforts to meet global food needs. Unfortunately, UC Davis professor Eduardo Blumwald misleads readers with assertions that genetically modified crops can feed the world.

In reality, the GE biotech industry has consistently failed to deliver on such promises. Industry data reveal that virtually 100 percent of commercial GE seeds have been engineered to either contain an insecticide or be used with herbicides. GE seeds are essentially the growth engine of the pesticide industry. It's a pity that UCD plant researchers still claim ignorance about the weight of global scientific evidence, which points towards ecological agriculture as our most reliable way to feed the world while conserving soil, water and biodiversity - resources critical to sustainable food production. Happily, ecological farming -- along with a rigorous commitment to democratic processes and equitable trade -- can succeed where narrow genetic fixes have failed.

-- Marcia Ishii-Eiteman, Oakland

Copyright The Sacramento Bee. All rights reserved.

What You Should Know About Comments on Sacbee.com

Sacbee.com is happy to provide a forum for reader interaction, discussion, feedback and reaction to our stories. However, we reserve the right to delete inappropriate comments or ban users who can't play nice. (See our full terms of service here.)

Here are some rules of the road:

Keep your comments civil. Don't insult one another or the subjects of our articles. If you think a comment violates our guidelines click the "Report Abuse" link to notify the moderators. Responding to the comment will only encourage bad behavior.

Don't use profanities, vulgarities or hate speech. This is a general interest news site. Sometimes, there are children present. Don't say anything in a way you wouldn't want your own child to hear.

Do not attack other users; focus your comments on issues, not individuals.

View original post here:
Ecological farming, not genetic engineering , will feed the world

Recommendation and review posted by Bethany Smith

REDWOOD CITY, Calif. and BOSTON, March 19, 2013 /PRNewswire/ --Ingenuity Systems, a leading provider of biomedical information and genomics analysis solutions, and GeneInsight, a wholly owned subsidiary of Partners HealthCare and a leading developer of software to support reporting for genetic testing laboratories, today announced that they will collaborate on an integrated workflow solution, encompassing the annotation, analysis, assessment and reporting of human variants from sequencing-based tests. The ability to provide the clinical laboratory market with a seamlessly integrated workflow to support next generation sequencing-based tests takes a significant step forward with this collaboration.

The current bottleneck for clinical laboratories offering NGS-based tests is the interpretation and clinical assessment of the genetic variants found in each patient. With strong annotation and filtration tools, the interpretative process becomes more scalable for gene panel, exome and whole genome data sets. Through the combined offering, Ingenuity will provide content and software for the analysis and biological interpretation of variants from sequencing-based tests and the Ingenuity offering will be interfaced with the GeneInsight Suite. GeneInsight will provide genetic testing laboratories and providers with networked infrastructure to support interpretation, reporting, and management of genetic data.

"The combined solution will incorporate knowledge about genomic variation from the Ingenuity offering with GeneInsight's knowledge management and reporting infrastructure, helping to streamline the overall workflow for very broad spectrum tests," said Heidi Rehm, PhD, Chief Laboratory Director, Partners' Laboratory for Molecular Medicine. "With the collaboration between GeneInsight and Illumina announced last fall, this truly integrated solution will go a long way towards making NGS-based technology more accessible in the clinic."

According to Doug Bassett, Chief Scientific Officer and Chief Technology Officer, Ingenuity Systems, "Clinical assessment of variants is all about the contentquickly and accurately evaluating relevant literature, databases and prior clinical observations to identify clinically relevant and actionable variants. The synergy of Ingenuity's extensive Knowledge Base of expert-curated clinical literature content with GeneInsight's knowledge management infrastructure and clinical reporting capabilities is a powerful combination for reference labs looking to streamline and scale variant assessment for sequence-based tests."

About Ingenuity SystemsIngenuity Systems is a leading provider of biomedical information and analysis solutionsfor the exploration, interpretation and analysis of complex biological systems inlife science research and molecular diagnostics.Today, Ingenuity's solutions are used by tens of thousands of researchers and clinicians at hundreds of leading pharmaceutical, biotechnology, academic, diagnostic and clinical institutions worldwide.

About GeneInsight, LLCGeneInsight LLC (www.geneinsight.com) is a wholly-owned subsidiary of Partners HealthCare. GeneInsight Suite was developed by Partners HealthCare in collaboration with leading geneticists, laboratory operations personnel, practicing physicians and IT professionals. GeneInsight has been in clinical use since 2005 and has supported the interpretation and reporting workflow for more than 28,000 complex genetic tests across multiple diagnostic reference laboratories, including Partners HealthCare Laboratory for Molecular Medicine.

About Partners HealthCarePartners HealthCare is an integrated health system founded by Brigham and Women's Hospital and Massachusetts General Hospital. In addition to its two academic medical centers, the Partners system includes community and specialty hospitals, a managed care organization, community health centers, a physician network, home health and long-term care services, and other health-related entities. Partners is one of the nation's leading biomedical research organizations and a principal teaching affiliate of Harvard Medical School.Partners HealthCare is a non-profit organization.

Read the original here:
Ingenuity Systems and GeneInsight to Deliver an Interpretation and Reporting Workflow Solution to Clinical Laboratories

Recommendation and review posted by Bethany Smith

SALT LAKE CITY & SAN CARLOS, Calif.--(BUSINESS WIRE)--

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory, and Natera, a leading innovator in reproductive and prenatal genetic testing, today announced that Nateras non-invasive prenatal screening test, Panorama, is available to ARUP clients nationwide.

The test is available for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnormalities, such as monosomy X (Turners syndrome).

Demand for non-invasive prenatal testing continues to grow, especially following the recommendation by the American Congress of Obstetricians and Gynecologists of use of the tests in high-risk pregnancies, said Edward Ashwood, M.D., president and CEO of ARUP. We are very pleased to partner with Natera to offer non-invasive prenatal testing to physicians and patients.

Added Matthew Rabinowitz, Ph.D., chief executive officer of Natera, Panorama has shown it has superior sensitivity and specificity compared to other non-invasive prenatal tests currently available, demonstrating that it is the best non-invasive prenatal testing choice for pregnant women today. We are pleased to partner with ARUP to enable Panorama to be offered to a broad network of hospitals, granting even more patients access to our best-in-class test.

ARUP is a national reference laboratory that provides tests to an extensive network of U.S.-based hospitals. ARUP's clients include more than half of the nation's university teaching hospitals and children's hospitals, as well as many other hospital networks and groups. Hospital laboratories provide patients with key tests that improve patient care, and are expected to play an increasingly important role in patient treatment as the use of molecular diagnostics grows. Hospital labs can order Panorama via ARUPs test code #2007537.

In clinical validation studies, Panorama demonstrated a sensitivity of greater than 99% when detecting common chromosomal abnormalities such as trisomy 21, trisomy 18 and trisomy 13; and 92% when detecting monosomy X. In addition, the Panorama test has had no false positives for all the syndromes tested in three clinical trials. The test uses fetal cell-free DNA found in maternal blood and works as early as nine weeks gestation. Panoramas clinical validation data was presented at the annual Society of Maternal Fetal Medicine Meeting on Feb. 15, 2013.

Panoramas technology analyzes, in a single reaction, 19,500 single nucleotide polymorphisms (SNPs), which are the most informative portions of an individuals DNA. It utilizes the NATUS [Next-generation Aneuploidy Testing Using SNPs] algorithm, an advanced version of Nateras proprietary informatics. Panorama has been validated globally and is currently being evaluated in several other clinical trials for the detection of genetic disorders, including trisomy 21, trisomy 18, trisomy 13, monosomy X, XXY, XYY, XXX and triploidy. The test uses a simple blood draw from the mother and can be performed within the first trimester of pregnancy, as early as nine weeks, without any risk to the fetus.

About Natera

Natera is a genetic testing company that has developed a proprietary bioinformatics-based technology (NATUS) to deliver accurate and comprehensive high-throughput testing for reproductive indications from tiny quantities of DNA. Natera operates a CLIA-certified laboratory in San Carlos, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include pre-implantation genetic diagnosis to identify chromosomal anomalies or inherited genetic conditions in embryos generated during an IVF cycle; products-of-conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause of the pregnancy loss; non-invasive prenatal testing to determine paternity; carrier screening tests to detect whether parents carry genetic variations that may result in disease in the child; and Panorama, a safe, simple test for pregnant women that identifies the most common chromosomal anomalies in a fetus as early as nine weeks. Natera's PreNATUS clinical trial for non-invasive screening of fetal chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. For more information, visit http://www.natera.com.

More here:
ARUP Laboratories Announces Availability of Natera’s Non-Invasive Prenatal Test, Panorama™

Recommendation and review posted by Bethany Smith

WORCESTER, Mass. and MADISON, N.J., March 18, 2013 /PRNewswire/ --Athena Diagnostics, a leader in neurological diagnostics, today announced the clinical availability of new genetic tests to aid the detection of several rare neurological disorders, including hereditary neuropathy, neuromuscular disease, epilepsy and certain movement disorders. The lab-developed tests are available through Athena Diagnostics, a business of Quest Diagnostics (DGX), the world's leading provider of diagnostic information services.

The testswill be unveiled during the American Academy of Neurology Annual Meeting in San Diego, March 16-23, 2013 (Booth 1413).

The tests streamline the diagnostic process by using gene sequencing andbioinformatics to evaluate many clinically-relevant genes with a single blood draw. Test reports provide information to assist clinicians and genetic counselors in confirming a diagnosis, developing a targeted treatment plan and managing patient care.

The new services include expanded testing for Charcot-Marie-Tooth disease (CMT), a hereditary motor sensory neuropathy for which early accurate diagnosis is critical to ensure patients avoid contra-indicated medications which can worsen symptoms.They also include DNA sequencing tests for myofibrillar myopathy (MFM), a debilitating disease that can lead to cardiac and respiratory complications, but is often confused with CMT and other conditions.Athena provides a broad diagnostic menu for MFM that may help physicians identify the disorder, hastening the use of aggressive supportive care that may maximize functional activity and prolong life expectancy.

In addition, the company is offering new tests for hereditary sensory and autonomic neuropathy (HSAN), hereditary neuralgic amyotrophy (HNA), hypokalemic periodic paralysis (HOKPP), limb girdle muscular dystrophy (LGMD), benign familiar infantile epilepsy and familial paroxysmal kinesigenic dyskinesia (FPKD).

Athena Diagnostics' clinical laboratory in Worcester, Mass. developed, validated and now offers the new tests.

"The genetic causes of neurological disorders are sometimes difficult to diagnose without reliable tests that are guided by specific clinical phenotypes," said Joseph J. Higgins, MD, FAAN, medical director for Quest Diagnostics Neurology and Athena Diagnostics. "In addition, overlapping clinical signs and symptoms in certain rare, neurogenetic disorders present a different challenge for physicians. The new test servicesfor evaluating epilepsy and neuromuscular disorders will aid physicians in diagnosing these diseases, some of whichmay be amenable to treatment,and assist in the diagnosis of other potentially affected family members.The results will also better prepare patients and their families to make informed life decisions based on their health risks."

In addition,scientists from Athena Diagnostics with report new research findings during the conference. The presentations include results of a study with experts from Penn State College of Medicineon the relative prevalence of subtypes of limb girdle muscular dystrophies(poster PO7.030). The study,based on nearly500 test results, is believed to be the largest cohort of genetically confirmed LGMD cases.

The newtests and researchbuild on Athena's leadership in diagnosticinformation servicesfor rare and esoteric disorders. Athena Diagnostics was the first laboratory company to offer a clinically validated C9orf72 genetic test to aid in the diagnosis of familial and sporadicamyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

Athena Diagnostics is also a leader in genetic testing services for dementia, including Alzheimer's disease. Quest Diagnostics today unveiled a neurology test panel for aiding the detection of secondary causes of dementia.Medical experts at Athena Diagnostics advised Quest's scientists on the panel's concept.

Read the original here:
Athena Diagnostics Announces New Genetic Testing Services for Rare Neurological Disorders

Recommendation and review posted by Bethany Smith

Public release date: 18-Mar-2013 [ | E-mail | Share ]

Contact: Shawna Williams shawna@jhmi.edu 410-955-8236 Johns Hopkins Medicine

A new online database combining symptoms, family history and genetic sequencing information is speeding the search for diseases caused by a single rogue gene. As described in an article in the May issue of Human Mutation, the database, known as PhenoDB, enables any clinician to document cases of unusual genetic diseases for analysis by researchers at the Johns Hopkins University School of Medicine or the Baylor College of Medicine in Houston. If a review committee agrees that the patient may indeed have a previously unknown genetic disease, the patient and some of his or her family members may be offered free comprehensive genetic testing in an effort to identify the disease culprit.

"PhenoDB is much more useful than I even thought it would be," says Ada Hamosh, M.D., M.P.H., a professor in the McKusick-Nathans Institute of Genetic Medicine at the Johns Hopkins University School of Medicine. "Bringing all of this information together is crucial to figuring out what our genetic variations mean." The database is designed to capture a bevy of standardized information about phenotype, which Hamosh defines as "any characteristic of a person" symptoms, personal and family health history, appearance, etc.

Hamosh and others developed PhenoDB for the Baylor-Hopkins Center for Mendelian Genomics (BHCMG), a four-year initiative that, together with its counterparts at Yale University and the University of Washington, is charged with uncovering the genetic roots of every disorder caused by a single faulty gene. There are an estimated 3,000 inherited disorders that have been described phenotypically in scientific papers but whose genetic causes have not yet been pinpointed, Hamosh says, but since many single-gene disorders are extremely rare, she suspects that many more have not yet made it into the literature.

The Centers for Mendelian Genomics have a powerful tool at their disposal, known as whole-exome sequencing. Just a few years ago, Hamosh explains, a geneticist trying to diagnose the cause of an inherited disease would have made an educated guess based on the patient's signs and symptoms about which gene might be at fault, and ordered a test of that gene. If the test came back negative for a mutation, she would order a test of a different gene, and so on. But whole-exome sequencing, in which about 90% of a person's genes are sequenced at one time, has been growing steadily cheaper, and it is this tool that the Centers will use to capture genetic sequencing information (whole-genome sequencing is the next step, but it remains too expensive for many uses, Hamosh notes, as it includes all of a person's DNA, most of which contains no genes).

However, making sense of the deluge of data yielded by whole-exome sequencing presents its own challenges. "The average person has tens of thousands of variations from the standard genetic sequence," Hamosh explains, "and we don't know what most of those variations mean." To parse these variations, she says, "one of the things that needs to change is that the lab doing the testing needs to have the whole phenotype, from head to toe." Researchers will then be better equipped to figure out which variations may or may not be relevant to a patient's illness. Another advantage of the database is that it enables colleagues at distant locations such as Baylor and Johns Hopkins to securely access the information and collaborate. Hamosh notes that the database enables different users to be afforded different levels of access for example, a health provider will only be able to see the information he or she has entered and that information is deidentified to protect patient privacy. In addition, providers must have patients' consent to be included in PhenoDB.

PhenoDB would be useful for any research project that seeks to match genomic information with its phenotypic effects, Hamosh says, and with that in mind, the Baylor-Hopkins Center for Mendelian Genomics has made the PhenoDB software available for free download at http://phenodb.net. She predicts that similar tools will soon be incorporated into electronic health records as well, so that "doctors will have patients' genomic information at their fingertips and can combine that with information about health history, disease symptoms and social situation to practice truly individualized medicine."

###

Other authors on the paper are Nara Sobreira, Julie Hoover-Fong, Corinne Boehm and David Valle, all of the Johns Hopkins University School of Medicine; V. Reid Sutton of Baylor College of Medicine; and Franois Schiettecatte of FS Consulting.

Go here to see the original:
New database to speed genetic discoveries

Recommendation and review posted by Bethany Smith

FIVE POINTS, Calif., March 18, 2013 /PRNewswire/ -- S&W Seed Company (SANW) announced, through a press release issued on Sunday, March 17th, that it has agreedtopurchase 100% ofSeed Genetics InternationalPty Ltd("SGI"), subject to due diligence and other customary conditions.The combination of S&W with Adelaide, Australia-based SGI will create the world 's largest non-dormant alfalfa seed company. The transaction, which is valued at approximately $16 million, is scheduled to close in early April 2013 and is expected to be immediately accretive to S&W's earnings.

Mark Grewal, president and chief executive officer of S&W Seed Company, commented, "This pact creates a powerhouse that will be unrivaled in its ability to breed and produce non-dormant alfalfa seed all year round.SGI has a tremendous base of contracted growers, very strong customer relationships, andunique genetics.The sales channels that S&W and SGI sell into are highly complementary,with very little overlap in customers. This move considerably strengthens our reach into Argentina and the rest of Latin America."

Grewal added, "I also want to stress the 'people factor.'S&W is gaining a highly competitive team of veteran seedsmen whom we know well and highly respect. We look forward to collaboration with them in all areas. By putting growers first, SGI's breeding program, initiated by Dr. Ross Downes and now continued by David Pengelly, has created grower-focused varieties that produce more seed per acre for the seed farmer than any other varieties in Australia, adding to seed farmer profits and potentially lowering cost of seed for S&W. We have the opportunity to merge David's work with that of S&W's own VP of Genetics and Breeding, Dan Gardner and our emeritus breeder,Bob Sheesley, who himself did pioneering work in salt tolerance and seed yield."

S&W is paying a purchase price ofapproximately $16million, over half of which consists of 865,000 shares S&W Common Stock and will result in SGI's owners becoming significant shareholders of S&W. The remaining considerationconsists of $5million in cash and$3million in the form of athree-yearpromissory note.Based on unaudited information, SGI hadrevenues of approximately AUD $18million for the fiscal year ended June 30, 2012 andhadpre-tax income of$1.6 million. SGI's assets consist primarily of accounts receivable, inventory, a tenured grower base and intellectual property, such as genetics.S&W intends to file audited financial resultsofSGIno later than 74 daysfrom closing,in compliance with SEC guidelines.

SGIcontrols approximately17,000 acres of irrigated alfalfa seed production under contract, and has first call on another 12,000acres of non-irrigated land that is rain dependent and has intermittent production. Australian seed yields per acre, even on irrigated fields, typically are materially lower than S&W's California yields and production costs are also materially lower.In 2013, SGIcontracted for alfalfa seed production with approximately 140contractfarmersin Southern Australia, all for SGI's proprietary varieties.In fiscal 2012, SGI's growers producedapproximately 5.5 million pounds, concluding a growing season that suffered from the impact of highly adverse weather conditions. The 2013 harvest is currently ongoing, but based on initial estimates, SGI managementis estimating that it will have approximately 8million pounds of alfalfa seed available for sale when the harvest concludes in late April 2013. Actual production could vary materially in either direction from estimates, due to unforeseen weather events and other factors.

SGIsells intointernational markets, includingthe Middle East and Africa (MENA), South America, and Southern Europe with the majority of the company's sales concentrated in the April through September time frame.

SGI was founded in 2002, with the goal of commercializing a seed breeding breakthrough by Dr. Ross Downes. Working with alfalfa in the mid 1990's, Dr. Downes had identified a particular trait that resulted in dramatically increased seed yields, even with less than optimum pollinator activity. The intellectual property stemming from Dr. Downes' pioneering work, which has been protected under international law and the Australian Plant Breeders Rights Act, became the cornerstone for over a decade of development by SGI's David Pengelly. SGI has developed well known proprietary varieties, such asSuperSonic, SuperNova, SuperStar, SuperCharge, SuperAurora, SuperSequal and SuperSiriver. Starting in 2002, the varieties developed by SGI quickly attracted a grower base that by 2012 enabled SGIto exceed 60%of Australian alfalfa seed production.SGI'salfalfa seed varieties are bred to resist disease, have tolerance to salt, create persistence in the field, and produce high seed yields in Australian production.The company also has a number of developments within its breeding program pertaining to dormant alfalfa varieties, tropical alfalfa seed varieties, and ease of pollination.

SGI, like S&W, considers the goodwill of its seed grower base to be of premier importance. SGI's contracts with seedfarmers under long term contracts that typically have initial terms of six years, extendable to ten years. To manage risk for itself and its growers, seed pricing is not fixed by contract, but instead based upon pooled production which is sold over an entire season, with a view to optimizing the prices realized. Due to its Southern Hemisphere location,SGIharvests seed in March through April, which is counter cyclical to S&W's July through October production in the Northern Hemisphere. The combined company will have the competitive advantages of year round production, which extends to all areas of the alfalfa seed business, including sales, inventory management and cash collection cycles.

Mark Harvey,Directorof Seed Genetics International, commented, "First, my thanks to S&W's Chairman, Grover Wickersham, and S&W's CFO, Matt Szot, for their long visits to Australia and their patience in negotiating over the last half year. While this is obviously a big move for us, the directors and management of SGI are trulyexcited about the advantages of a combined S&W/SGI and we want the challenge of continuing to build on what the four partners started."

Mr. Harvey expanded, "For our Australian growers, this means we willbeexpanding production under the umbrella of a public company with a strong balance sheet and financial resources. We also gain access to S&W's proven proprietary genetics. We look forward to collaborating with S&W's well respected breeder, Dan Gardner, who is well known by our own David Pengelly and Ross Downes. When we learned last year that Dan and our tough and respected sales and marketing competitor from IVS, Fred Fabre, had both joined S&W, it piqued ourinterest."

More:
Investor Advisory: S&W Seed Company To Acquire Seed Genetics International

Recommendation and review posted by Bethany Smith

Seattle Genetics, Inc. (SGEN) recently announced the submission of a supplemental biologics license application (sBLA) to the US Food and Drug Administration (:FDA) for the use of Adcetris (brentuximab vedotin) in the retreatment of patients and for extended duration of use beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).

The sBLA was based on results from a phase II study. The study had two treatment arms. One arm evaluated retreatment with Adcetris in patients who had responded to Adcetris treatment earlier, then discontinued treatment and as a result suffered disease progression or relapse. The other arm evaluated prolonged treatment with Adcetris beyond 16 cycles of therapy.

Adcetris was approved by the FDA in Aug 2011 for the treatment of patients with HL after failure of autologous stem cell transplant (:ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris was also approved for sALCL in treatment-experienced patients. In Oct 2012, Adcetris gained EU approval as well for the same indications.

In Jan 2013, a global phase III study (ECHELON-2) was initiated on Adcetris. In this study, Adcetris plus chemotherapy will be evaluated for the front-line treatment of CD30-positive mature T-cell lymphoma (:MTCL) including patients with sALCL and other types of peripheral T-cell lymphomas.

In Feb 2013, Adcetris received approval under Health Canada's Notice of Compliance with conditions (NOC/c) for the treatment of relapsed or refractory HL and sALCL.

Our Take

We are positive on Seattle Genetics efforts to expand Adcetris label. Adcetris net product revenue in the fourth quarter of 2012 was $35.4 million.

Seattle Genetics carries a Zacks Rank #3 (Hold). Right now, Cytokinetics, Inc. (CYTK), Osiris Therapeutics, Inc. (OSIR), and XOMA Corporation (XOMA) look more attractive with a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on OSIR

Read the Full Research Report on XOMA

See more here:
SGEN Seeks Adcetris Label Expansion

Recommendation and review posted by Bethany Smith

Seattle Genetics has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration supporting the use of ADCETRIS for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of HL and sALCL, that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL. The sBLA is based on results from a phase II clinical trial with two treatment arms. One arm evaluated retreatment with ADCETRIS in patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse. The other arm allowed treatment extension and evaluated prolonged treatment with ADCETRIS beyond 16 cycles of therapy. The sBLA submission includes updated data sets from this phase II trial. Preliminary data from this trial were previously reported at the 2011 American Society of Hematology Annual Meeting and at the 2012 American Society of Clinical Oncology Annual meeting.

Go here to see the original:
Seattle Genetics submits sBLA to FDA for ADCETRIS

Recommendation and review posted by Bethany Smith

BOTHELL, Wash.--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) announced today that it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) supporting the use of ADCETRIS (brentuximab vedotin) for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of HL and sALCL, that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL.

The sBLA submission includes data demonstrating ADCETRIS activity in managing HL and sALCL when used in the retreatment setting, as well as beyond the 16 cycles described in our current label, while retaining a manageable safety profile, said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Our goal is to broaden the ADCETRIS U.S. labeling claims to provide both patients and physicians the opportunity to incorporate ADCETRIS into additional HL and sALCL treatment settings. The sBLA submission includes data that support these uses and we look forward to the regulatory outcome.

The sBLA is based on results from a phase II clinical trial with two treatment arms. One arm evaluated retreatment with ADCETRIS in patients who previously responded to treatment with ADCETRIS, then discontinued treatment and subsequently had disease progression or relapse. The other arm allowed treatment extension and evaluated prolonged treatment with ADCETRIS beyond 16 cycles of therapy. The sBLA submission includes updated data sets from this phase II trial. Preliminary data from this trial were previously reported at the 2011 American Society of Hematology (ASH) Annual Meeting and at the 2012 American Society of Clinical Oncology (ASCO) Annual meeting.

At the 2012 ASCO Annual Meeting, retreatment data from the phase II trial were reported from 23 patients, including one patient who was treated twice. Patients had received a median of four prior systemic therapies, including ADCETRIS. Of 23 evaluable patients, 70 percent (16 of 23) achieved an objective response after retreatment with ADCETRIS, including nine complete remissions and seven partial remissions. Median duration of retreatment objective response was 8.8 months. Among retreated HL patients, nine of 16 (56 percent) achieved an objective response. Among retreated sALCL patients, seven of eight (88 percent) achieved an objective response. The most common adverse events were peripheral neuropathy (46 percent), nausea (42 percent), fatigue (38 percent), diarrhea (33 percent) and fever (29 percent).

At the 2011 ASH Annual Meeting, prolonged treatment data were reported from 17 patients with a median duration of treatment of 17.3 months (approximately 24 cycles of every three week dosing). The overall objective response rate with extended treatment was 88 percent, including 76 percent complete remissions and 12 percent partial remissions. ADCETRIS was generally well-tolerated, with the most common adverse events being peripheral neuropathy (71 percent), upper respiratory infection (53 percent) and fatigue (47 percent). Prolonged treatment with ADCETRIS was associated with clinically meaningful durations of response without worsening of toxicity over time.

ADCETRIS is currently not approved for retreatment and extended duration beyond 16 cycles of therapy in relapsed HL and sALCL.

About Lymphoma

Lymphoma is a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell generally expresses CD30. Systemic ALCL is an aggressive type of T-cell non-Hodgkin lymphoma that also expresses CD30.

About ADCETRIS

Go here to see the original:
Seattle Genetics Submits Supplemental BLA to FDA for Retreatment and Extended Duration of Therapy with ADCETRIS® ...

Recommendation and review posted by Bethany Smith

By Carol Davis

PUBLISHED: 19:49 EST, 18 March 2013 | UPDATED: 19:49 EST, 18 March 2013

A new form of gene therapy could help thousands with an inherited eye condition that leads to blindness and possibly treat age-related macular degeneration and glaucoma.

Nick Tuftnell, 36, an IT consultant from Bristol, was the third in the world to have the operation.

'Over the next few years, my peripheral vision became worse,' said Nick Tuftnell

My grandfather was partially sighted, so Ive always known eye disease runs in the family. I remember having to watch out for him when I was younger.

When I was a teenager rushing to a cricket match at Lords, I forgot to warn him about a kerb, so he tripped.

But because my vision was fine, I didnt worry about myself too much until I was 17 and wanted my driving licence.

To check I could see properly, and aware of my family history, my ophthalmologist referred me to the specialist my grandad saw at Moorfields Eye Hospital in London.

Although my vision was fine, the specialist confirmed what wed suspected that like my grandad, I had choroideremia.

View post:
Eye condition: Injecting a virus into my eye saved my sight

Recommendation and review posted by Bethany Smith

BOSTON - A unique new cancer treatment uses gene therapy to induce a cancer-fighting immune response whose intensity can then be controlled with a pill. The combination could help tailor treatment to a patients individual response.

The treatment uses the bodys own cells or tumor cells to produce extra copies of a naturally occurring hormone-like molecule called IL-12, which regulates anticancer immune responses. Last week, Ziopharm Oncology announced a clinical study of the treatment for patients with breast cancer. The company is already testing it in patients with melanoma.

Many researchers have explored techniques that rev up the natural response the body uses to detect and attack cancerous cells (see, for example, Engineering Better Immune Cells and Priming the Body to Tackle Cancer). But controlling the killer cells of the immune system can sometimes be a challenge, as researchers found in the 1990s when cancer patients who were given IL-12 in a clinical trial died from toxic side effects.

IL-12 is a very potent [immune system regulator] and can generate a lot of side effects, says Per Basse, a physician-scientist at the University of Pittsburgh School of Medicine, who studies immune cells and their ability to fight cancer. As a clinician, I would like to be able to dial it up and down so that if it all starts to look not so good, you can stop the process, he says.

To avoid the dangerous side of the molecule, Ziopharms system is designed to control IL-12 with a combined genetic and pharmaceutical switch. A virus is injected into the tumor to deliver the gene for IL-12. The gene starts out in off mode, so it doesnt actually produce any IL-12. To activate the gene, a patient has to take a pill that delivers another molecule. The advantage is that any patient who starts to experience nasty side effects from the IL-12 can stop taking the pill. If things go awry, you have an escape valve, says Ziopharms CEO, Jonathan Lewis.

The key to the inducible system is a version of the receptor that controls molting in arthropods (insects, spiders, and crustaceans), modified so that it determines whether the IL-12 gene is on. The gene for that receptor, which is also delivered into the body by a virus, is always on, but its protein product and thus IL-12 expression is activated by the pill. Ziopharm licensed the control system from Intrexon for use in its oncology treatment.

The inducibility is a great idea, but the trick is getting something that you can get into the tumor, says Ralph Weichselbaum, a cancer researcher at the University of Chicago, who has worked on a cancer therapy induced by radiation. Currently, Ziopharm injects the gene-toting virus directly into patients tumors, but Lewis says the plan is to inject it into muscles in the future. Muscle cells are extremely good protein production factories, he says.

But even injecting the virus into a single tumor has an effect on other tumorsboth in lab animals and in humans. In animal studies, the tumor that receives the injection will at first get bigger because immune cells are accumulating in response to the IL-12. Then it will get smaller and go away, says Lewis. Tumors that received no injection will do the same thinggrow, then shrink, and then disappear. We are seeing similar things in people, says Lewis.

Eventually, the system could be used to deliver multiple genetic treatments at once, says Lewis. With one injection you could be able to control three or four [cancer-fighting] proteins in different ways.

Read the rest here:
Cancer gene therapy activated by a pill provides personalized treatment

Recommendation and review posted by Bethany Smith

Osmosis | Osmosis Skin Care | Cell Therapy
http://www.skincarebyalana.com/osmosis.html Alana interviews osmosis pur medical skin care cell therapy.

By: Alana Mitchell

See more here:
Osmosis | Osmosis Skin Care | Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Osmosis | Osmosis Skin Care | ATP Cell Therapy
Osmosis | Osmosis Skin Care | ATP Cell Therapy. Uploaded by Alana Mitchell on Mar 14 2013. httpwwwskincarebyalanacomosmosishtml Alana interviews osmosis pur medical skin care founder about ATP Cell Therapy.

By: Alana Mitchell

Read this article:
Osmosis | Osmosis Skin Care | ATP Cell Therapy - Video

Recommendation and review posted by Bethany Smith

Stewart Brand: The dawn of de-extinction. Are you ready?
Throughout humankind #39;s history, we #39;ve driven species after species extinct: the passenger pigeon, the Eastern mountain lion, the dodo .... But now, says Stew...

By: TEDtalksDirector

Excerpt from:
Stewart Brand: The dawn of de-extinction. Are you ready? - Video

Recommendation and review posted by Bethany Smith

March 18, 2013, 3 a.m.

There was no doubt in Chontell Johnson's mind. When a genetic test revealed her mother had early onset Alzheimer's, the then-27-year-old decided she would get tested, too.

''If I didn't know, I would spend the rest of my life second-guessing decisions,'' she says.

The results confirmed that within the three billion letters of Johnson's genome, a single mistake means she has a 98 per cent chance of developing the neurological condition that killed her mother at 47.

''It scares the life out of me to think I'll not be able to communicate with people,'' says Johnson, now 33.

When the human genome was first sequenced 13 years ago, it was hailed as a medical revolution, the catalyst for this new era of personalised medicine.

For most of the past decade, however, genetic testing remained an expensive tool for research laboratories only.

But in recent years, the technology to read a person's genome has advanced at a staggering pace. Now a vial of spit or blood and an internet connection is all anybody needs to peer inside their body's blueprint.

But while labs can sequence a person's DNA in a couple of days for less than $1000 - compared with the original human genome project, which took a decade and cost more than $2 billion - interpreting a person's 23,000 or so genes into something meaningful for their future health has proved much more complex.

In a small fraction of diseases, such as cystic fibrosis, Huntington's disease and early onset familial Alzheimer's, genetic mutations are the direct cause. If you have the mutation (or mutations), there is no escaping the disorder.

Go here to see the original:
Living with a time bomb

Recommendation and review posted by Bethany Smith